Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03969303Completed

NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients

Role: collaborator

NCT01934920Unknown

Identifying Patients With Unrecognized Treatable Diabetic Macular Edema

Role: lead

NCT03609996Unknown

Retrospective Review of Proliferative Diabetic Retinopathy Patients

Role: lead

NCT01769183Phase 2Completed

Squalamine for the Treatment in Proliferative Diabetic Retinopathy

Role: lead

All 4 trials loaded